11 May 2012
EMA/281471/2012
Patient Health Protection

Announcement of European Medicines Agency priorities for adverse drug reaction research – 7th Call FP7

On 17 November 2011 the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted by written procedure its priorities for drug safety research based on recommendations from the CHMP's Pharmacovigilance Working Party. These priorities were subsequently forwarded to the European Commission for consideration as future topics for the 7th Call of the European Commission's 7th Framework Programme (FP7).

The Commission has recently published an Orientation Paper with proposed priorities for health research in 2013 for proposals of FP7. [ftp://ftp.cordis.europa.eu/pub/fp7/health/docs/fp7-health-2013-orientation-paper-120402_en.pdf]

Several of the EMA proposals for adverse drug reaction research have been considered in the Orientation paper and are reflected on page 45, under topic 4 "Other actions across the health theme – Adverse Drug Reaction Research".

The European Medicines Agency is now releasing complementary information in order to provide further details on the background to and the expected scope of proposed research opportunities.

The proposed priorities for health research included in the Commission's Orientation Paper are:

- Long term safety effects of antipsychotics in patients with dementia
- Long term adverse skeletal effects of bisphosphonates
- DNA collection and studies on the genetic causes of adverse drug reactions: angiotensin-converting enzyme inhibitor related angioedema, and statin-induced myopathy

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8660
E-mail info@ema.europa.eu **Website** www.ema.europa.eu